Press release
Medullary Thyroid Cancer Pipeline Insights, Clinical Trials Analysis, FDA Approvals, and Emerging Drugs 2023 | Major Companies- Bristol-Myers Squibb, Takeda, NantCell Inc, and Others
Medullary Thyroid Cancer Pipeline
Key takeaways from the Medullary Thyroid Cancer Pipeline Insight Report
• Over 15+ Medullary Thyroid Cancer companies are evaluating 15+ Medullary Thyroid Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Medullary Thyroid Cancer market would significantly increase market revenue.
• The Medullary Thyroid Cancer Companies includes Bristol-Myers Squibb, Takeda, NantCell, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Bayer, Novartis, Hutchison Medipharma Limited, Turning Point Therapeutics Inc., and others.
• Promising Medullary Thyroid Cancer Pipeline Therapies includes Selpercatinib, Cabozantinib (XL184) 140 mg, Vandetanib 300 mg, Anlotinib, Caprelsa, XL184, omeprazole, ranitidine, ZD6474 (vandetanib), and others.
• The Medullary Thyroid Cancer companies and academics are working to assess challenges and seek opportunities that could influence Medullary Thyroid Cancer R&D. The Medullary Thyroid Cancer pipeline therapies under development are focused on novel approaches to treat/improve Medullary Thyroid Cancer.
Request a sample and discover the recent breakthroughs happening in Medullary Thyroid Cancer Pipeline Landscape @ Medullary Thyroid Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Medullary Thyroid Cancer Overview
Medullary thyroid cancer, or MTC, is a cancer that forms in the thyroid. The thyroid is a gland located in the front of your neck, just below the Adam's apple. It is responsible for sending out hormones to the rest of your body. The inside of the thyroid is called the medulla. The medulla contains special cells called parafollicular C cells that produce and release hormones.
Medullary Thyroid Cancer Emerging Drugs Profile
• Nivolumab: Bristol-Myers Squibb
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2. It releases PD-1 pathway-mediated inhibition of inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth. Currently, it is in Phase II stage of clinical trial evaluation to treat Medullary Thyroid Cancer.
• Regorafenib: Bayer
Regorafenib is a small-molecule multikinase inhibitor that specifically inhibits epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor-ß (PDGFRB), fibroblast growth factor receptor 1 (FGFR1), and the mutant oncogenic kinases KIT, RET, and B-RAF. Several clinical trials have studied the association between regorafenib response and angiogenesis biomarkers in blood. Higher concentrations of VEGF family ligands, such as PIGF, and lower levels of TIMP2, soluble VEGF receptor 2, and TIE-1 have been associated with the response to regorafenib. A biomarker analysis from the CORRECT clinical trial for regorafenib efficacy in patients with mCRC showed that in both KRAS wild-type and mutant statuses, low levels of circulating free DNA and high levels of TIE-1 in plasma were associated with a clinical benefit. Furthermore, the single-nucleotide polymorphism (SNP) rs2010963 in the VEGF-A gene correlated with an improved PFS and OS in this trial. Thus, genotyping analysis may be useful for the selection of patients who could potentially benefit from regorafenib treatment. Currently, it is in Phase II stage of clinical trial evaluation to treat Medullary Thyroid Cancer.
Find out more about the Medullary Thyroid Cancer Diagnosis and Treatment of patients @ Medullary Thyroid Cancer Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Medullary Thyroid Cancer Pipeline Therapies and Companies
• Bristol-Myers Squibb: Selpercatinib
• Takeda: Cabozantinib (XL184) 140 mg
• NantCell Inc: Vandetanib 300 mg
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd: Anlotinib
• CSPC ZhongQi Pharmaceutical Technology Co Ltd: Caprelsa
• Bayer: XL184
• Novartis: Omeprazole
• Hutchison Medipharma Limited: Ranitidine
• Turning Point Therapeutics Inc: ZD6474 (vandetanib)
Medullary Thyroid Cancer Pipeline Therapeutics Assessment
Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Discover more about the list of Medullary Thyroid Cancer FDA-approved drugs for Medullary Thyroid Cancer @ Medullary Thyroid Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Medullary Thyroid Cancer Pipeline Report
• Coverage- Global
• Medullary Thyroid Cancer Companies- Bristol-Myers Squibb (NYSE: BMY), Takeda (NYSE: TAK), NantCell, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Bayer (NYSE: BAY), Novartis (NYSE: NVS), Hutchison Medipharma Limited, Turning Point Therapeutics Inc.(NYSE: TPTX), and others.
• Medullary Thyroid Cancer Pipeline Therapies- Selpercatinib, Cabozantinib (XL184) 140 mg, Vandetanib 300 mg, Anlotinib, Caprelsa, XL184, omeprazole, ranitidine, ZD6474 (vandetanib), and others
• Medullary Thyroid Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for Medullary Thyroid Cancer Emerging Therapies and Ongoing Clinical Trials; visit @ Medullary Thyroid Cancer Emerging Therapies and Companies- https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Medullary Thyroid Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Medullary Thyroid Cancer - DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. Nivolumab: Bristol-Myers Squibb
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Medullary Thyroid Cancer Key Companies
15. Medullary Thyroid Cancer Key Products
16. Medullary Thyroid Cancer- Unmet Needs
17. Medullary Thyroid Cancer- Market Drivers and Barriers
18. Medullary Thyroid Cancer- Future Perspectives and Conclusion
19. Medullary Thyroid Cancer Analyst Views
20. Medullary Thyroid Cancer Key Companies
21. Appendix
For further information on the Medullary Thyroid Cancer Pipeline therapeutics, reach out @ Medullary Thyroid Cancer Market Drivers and Barriers- https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Medullary Thyroid Cancer Pipeline Insights, Clinical Trials Analysis, FDA Approvals, and Emerging Drugs 2023 | Major Companies- Bristol-Myers Squibb, Takeda, NantCell Inc, and Others here
News-ID: 3055091 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Medullary
Medullary Thyroid Cancer Market Outlook 2025-2034: Growth Trends, Pipeline Insig …
Medullary thyroid cancer (MTC) is a rare and aggressive form of thyroid cancer that originates from the parafollicular C-cells, responsible for producing calcitonin. Unlike the more common forms of thyroid cancer, MTC is often diagnosed at an advanced stage, making it a challenging condition to treat. As with many rare cancers, the prognosis for MTC patients is highly variable, and the need for more effective therapies has driven significant research…
Medullary Thyroid Cancer Market Size, Growth, Forecast & Trends 2024-2034
Market Overview:
The medullary thyroid cancer market reached a value of US$ 141.1 Million in 2023 and expected to reach US$ 405.1 Million by 2034, exhibiting a growth rate (CAGR) of 10.06% during 2024-2034.
The report offers a comprehensive analysis of the medullary thyroid cancer market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in…
Medullary Thyroid Cancer Treatment Market 2020 Global Research Report, Size, Sha …
The global medullary thyroid cancer treatment market is likely to derive growth from recent advancements in diagnosis of the disease. According to a report by Fortune Business Insights, titled “Medullary Thyroid Cancer Treatment Market Size, Share and Global Trend by Treatment Type (Chemotherapy, Immunotherapy), By Distribution Channel (Hospital Pharmacy, Retail pharmacy, Online pharmacy), and Geography Forecast till 2026,” the market will benefit from the high prevalence as well as the…
Medullary Thyroid Cancer Market Forecast, Overview and Cost Structure Analysis t …
The Medullary Thyroid Cancer Market report offers a deep analysis of the Medullary Thyroid Cancer trade. It demonstrates a quick outline of trade knowledge and key Information like Key Manufacturers , Types, Application, Table Of Content, etc of the market. The report highlights Top Venders from the worldwide and Medullary Thyroid Cancer Market along with their worth of the Industry to see their progress. The worldwide Medullary Thyroid Cancer analysis…
Global Medullary Thyroid Cancer Drugs Market Research Report 2016
This report studies Medullary Thyroid Cancer Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering
Sinofi Genzyme
Exelixis
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Medullary Thyroid Cancer Drugs in these regions, from 2011…
Global Medullary Thyroid Cancer Drugs Market Research Report 2016
This report studies Medullary Thyroid Cancer Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering
Sinofi Genzyme
Exelixis
Fill the form for an exclusive sample of this report @ http://www.qyresearchreports.com/sample/sample.php?rep_id=904006&type=E
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth…
